February 18, 2021 08:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Avoro Ventures announced today that Sara Nayeem, MD, has joined the firm as a Partner, focused on its venture capital investment efforts. Dr. Nayeem joins Avoro Ventures after 12 years with New Enterprise Associates, Inc. (NEA), where she was a Partner in the firm’s biopharma …
Arsani William, M.D., of Logos Capital, and John Schmid, Biotech Industry Veteran, Appointed to the Company’s Board of Directors January 27, 2021 08:30 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide …
NEWS PROVIDED BY IO Biotech Jan 13, 2021, 02:00 ET COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ — IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare …
– Financing in Support of Company’s Goal of Developing Targeted Therapies to Improve the Lives of Women with Cancer – Lead Investor Vivo Capital is Joined by Additional New Investors Avoro Capital Advisors, Funds and Accounts Managed by BlackRock, Deerfield Management Company and OrbiMed, and All Existing Institutional Investors News provided by Olema Pharmaceuticals, Inc …
Gilead Sciences to Acquire Immunomedics — Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors — — Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and Best-in-Class Potential — — Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology …
110 Greene Street, Suite 800
New York, NY 10012
+1 212.937.4970
info@avorocapital.com